Gastrointestinal Cancer Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Gastrointestinal Cancer Trials Currently Recruiting Participants (Esophagus, Stomach, Biliary System, Pancreas, Small Intestine, Large Intestine, Rectum and Anus)

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA2142	Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas	Jennifer R. Eads, MD, Chair George Fisher, MD, PhD, Co-Chair	126	11/06/2015	EA2142 Resources
EA2161	A Phase II Study of the mTOR Inhibitor TAK-228 (formerly MLN0128) in Patients with Advanced Pancreatic Neuroendocrine Tumors That are Resistant to Rapalogs	Lakshmi N. Rajdev, MD, MS, Chair Steven K. Libutti, MD, Co-Chair Al B. Benson, III, MD, PhD, Co-Chair (Paul J. Catalano, ScD)	40	02/01/2017	EA2161 Resources
EA2165	A Randomized Phase II Study of Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage 11-111 B Anal Cancer	Lakshmi N. Rajdev, MD, MS, Chair Peter J. O'Dwyer, MD, Co-Chair Al B. Benson, III, MD, PhD, Co-Chair (Paul J. Catalano, ScD)	200	04/13/2018	EA2165 Resources
7151	Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of National CT Colonography Trial Data *Patient recruitment by invitation only* Note: This trial is a substudy of A6664, the national CT colonography screening trial of healthy participants. A7151 is funded by the ACRIN Fund for Imaging Innovation.	Hanna M. Zafar, MD, MHS, Chair William C. Black, MD, Co-Chair (Jeremy Gorelick, PhD)	520	09/16/2011	7151 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA2142 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Jennifer R. Eads, MD, Chair
George Fisher, MD, PhD, Co-Chair 126 11/06/2015 EA2142 Resources

EA2161 A Phase II Study of the mTOR Inhibitor TAK-228 (formerly MLN0128) in Patients with Advanced Pancreatic Neuroendocrine Tumors That are Resistant to Rapalogs Lakshmi N. Rajdev, MD, MS,
Chair
Steven K. Libutti, MD, Co-Chair
Al B. Benson, III, MD, PhD, Co-Chair
(Paul J. Catalano, ScD) 40 02/01/2017 EA2161 Resources

EA2165 A Randomized Phase II Study of Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage 11-111 B Anal Cancer Lakshmi N. Rajdev, MD, MS,
Chair
Peter J. O'Dwyer, MD, Co-Chair
Al B. Benson, III, MD, PhD, Co-Chair
(Paul J. Catalano, ScD) 200 04/13/2018 EA2165 Resources

7151 Incidence and Significance of Extracolonic Findings on CT Colonography:
Retrospective Analysis of National CT Colonography Trial Data

***Patient recruitment by invitation only***

Note: This trial is a substudy of A6664, the national CT colonography screening trial of healthy participants. A7151 is funded by the ACRIN Fund for Imaging Innovation. Hanna M. Zafar, MD, MHS, Chair
William C. Black, MD, Co-Chair
(Jeremy Gorelick, PhD) 520 09/16/2011 7151 Resources

Download